|
1
|
Vose J, Armitage J and Weisenburger D;
International T-Cell Lymphoma Project: International peripheral
T-cell and natural killer/T-cell lymphoma study: Pathology findings
and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Au W-Y, Ma S-Y, Chim C-S, Choy C, Loong F,
Lie AK, Lam CC, Leung AY, Tse E, Yau CC, et al: Clinicopathologic
features and treatment outcome of mature T-cell and natural
killer-cell lymphomas diagnosed according to the World Health
Organization classification scheme: A single center experience of
10 years. Ann Oncol. 16:206–214. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
No authors listed. A clinical evaluation
of the International Lymphoma Study Group classification of
non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification
Project. Blood. 89:3909–3918. 1997.PubMed/NCBI
|
|
4
|
Takahashi E, Ohshima K, Kimura H, Hara K,
Suzuki R, Kawa K, Eimoto T and Nakamura S; NK-cell Tumor Study
Group: Clinicopathological analysis of the age-related differences
in patients with Epstein-Barr virus (EBV)-associated extranasal
natural killer (NK)/T-cell lymphoma with reference to the
relationship with aggressive NK cell leukaemia and chronic active
EBV infection-associated lymphoproliferative disorders.
Histopathology. 59:660–671. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carbone A, Gloghini A and Dotti G:
EBV-associated lymphoproliferative disorders: Classification and
treatment. Oncologist. 13:577–585. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cohen JI, Bollard CM, Khanna R and
Pittaluga S: Current understanding of the role of Epstein-Barr
virus in lymphomagenesis and therapeutic approaches to
EBV-associated lymphomas. Leuk Lymphoma. 49(Suppl 1): 27–34. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kohrt H and Advani R: Extranodal natural
killer/T-cell lymphoma: Current concepts in biology and treatment.
Leuk Lymphoma. 50:1773–1784. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Raab-Traub N: Epstein-Barr virus
transforming proteins: biologic properties and contribution to
oncogenesis. DNA Tumor Viruses. Springer; pp. 259–284. 2009,
View Article : Google Scholar
|
|
9
|
Strong MJ, Xu G, Coco J, Baribault C,
Vinay DS, Lacey MR, Strong AL, Lehman TA, Seddon MB, Lin Z, et al:
Differences in gastric carcinoma microenvironment stratify
according to EBV infection intensity: Implications for possible
immune adjuvant therapy. PLoS Pathog. 9:e10033412013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van Beek J, Zur Hausen A, Klein Kranenbarg
E, van de Velde CJ, Middeldorp JM, van den Brule AJ, Meijer CJ and
Bloemena E: EBV-positive gastric adenocarcinomas: A distinct
clinicopathologic entity with a low frequency of lymph node
involvement. J Clin Oncol. 22:664–670. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang YY, Koh LW, Tsai JH, Tsai CH, Wong
EF, Lin SJ and Yang CC: Correlation of viral factors with cervical
cancer in Taiwan. J Microbiol Immunol Infect. 37:282–287.
2004.PubMed/NCBI
|
|
12
|
Whitaker NJ, Glenn WK, Sahrudin A, Orde
MM, Delprado W and Lawson JS: Human papillomavirus and Epstein-Barr
virus in prostate cancer: Koilocytes indicate potential oncogenic
influences of human papillomavirus in prostate cancer. Prostate.
73:236–241. 2013. View Article : Google Scholar
|
|
13
|
Cao Y: Epstein-Barr virus encoded LMP1
regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in
CNE1 cells. J Exp Clin Cancer Res. 14:192013.
|
|
14
|
Ho CH, Chen CL, Li WY and Chen CJ: Decoy
receptor 3, upregulated by Epstein-Barr virus latent membrane
protein 1, enhances nasopharyngeal carcinoma cell migration and
invasion. Carcinogenesis. 30:1443–1451. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen R, Zhang D, Mao Y, Zhu J, Ming H, Wen
J, Ma J, Cao Q, Lin H, Tang Q, et al: A human Fab-based
immunoconjugate specific for the LMP1 extracellular domain inhibits
nasopharyngeal carcinoma growth in vitro and in vivo. Mol Cancer
Ther. 11:594–603. 2012. View Article : Google Scholar
|
|
16
|
Devergne O, Cahir McFarland ED, Mosialos
G, Izumi KM, Ware CF and Kieff E: Role of the TRAF binding site and
NF-kappaB activation in Epstein-Barr virus latent membrane protein
1-induced cell gene expression. J Virol. 72:7900–7908.
1998.PubMed/NCBI
|
|
17
|
Shair KH, Bendt KM, Edwards RH, Nielsen
JN, Moore DT and Raab-Traub N: Epstein-Barr virus-encoded latent
membrane protein 1 (LMP1) and LMP2A function cooperatively to
promote carcinoma development in a mouse carcinogenesis model. J
Virol. 86:5352–5365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang CF, Peng LX, Huang TJ, Yang GD, Chu
QQ, Liang YY, Cao X, Xie P, Zheng LS, Huang HB, et al: Cancer
stem-like cell characteristics induced by EB virus-encoded LMP1
contribute to radioresistance in nasopharyngeal carcinoma by
suppressing the p53-mediated apoptosis pathway. Cancer Lett.
344:260–271. 2014. View Article : Google Scholar
|
|
19
|
Aozasa K and Zaki MA: Epidemiology and
pathogenesis of nasal NK/T-cell lymphoma: A mini-review. Sci World
J. 11:422–428. 2011. View Article : Google Scholar
|
|
20
|
Zheng H, Li LL, Hu DS, Deng XY and Cao Y:
Role of Epstein-Barr virus encoded latent membrane protein 1 in the
carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol.
4:185–196. 2007.PubMed/NCBI
|
|
21
|
Shatsky IN, Dmitriev SE, Andreev DE and
Terenin IM: Transcriptome-wide studies uncover the diversity of
modes of mRNA recruitment to eukaryotic ribosomes. Crit Rev Biochem
Mol Biol. 49:164–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fischer PM: Cap in hand: Targeting eIF4E.
Cell Cycle. 8:2535–2541. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X, Zeng J, Zhou M, Li B, Zhang Y,
Huang T, Wang L, Jia J and Chen C: The tumor suppressive role of
miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer.
11:562012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
De Benedetti A and Harris AL: eIF4E
expression in tumors: Its possible role in progression of
malignancies. Int J Biochem Cell Biol. 31:59–72. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Benedetti A and Graff JR: eIF-4E
expression and its role in malignancies and metastases. Oncogene.
23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nasr Z, Robert F, Porco JA Jr, Muller WJ
and Pelletier J: eIF4F suppression in breast cancer affects
maintenance and progression. Oncogene. 32:861–871. 2013. View Article : Google Scholar
|
|
27
|
Oridate N, Kim HJ, Xu X and Lotan R:
Growth inhibition of head and neck squamous carcinoma cells by
small interfering RNAs targeting eIF4E or cyclin D1 alone or
combined with cisplatin. Cancer Biol Ther. 4:318–323. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
DeFatta RJ, Nathan CO and De Benedetti A:
Antisense RNA to eIF4E suppresses oncogenic properties of a head
and neck squamous cell carcinoma cell line. Laryngoscope.
110:928–933. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thornburg NJ, Kulwichit W, Edwards RH,
Shair KH, Bendt KM and Raab-Traub N: LMP1 signaling and activation
of NF-kappaB in LMP1 transgenic mice. Oncogene. 25:288–297.
2006.
|
|
30
|
Hariri F, Arguello M, Volpon L,
Culjkovic-Kraljacic B, Nielsen TH, Hiscott J, Mann KK and Borden
KL: The eukaryotic translation initiation factor eIF4E is a direct
transcriptional target of NF-kappaB and is aberrantly regulated in
acute myeloid leukemia. Leukemia. 27:2047–2055. 2013. View Article : Google Scholar : PubMed/NCBI
|
